Difference between revisions of "Epirubicin (Ellence)"
Jump to navigation
Jump to search
(updated content) |
m |
||
| (35 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. | + | Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. Inhibits DNA helicase activity, preventing enzymatic separation of double-stranded DNA.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050778s015s017s018lbl.pdf Epirubicin (Ellence) package insert]</ref><ref>[[:File:Epirubicin.pdf | Epirubicin (Ellence) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Bladder cancer]] |
*[[Breast cancer]] | *[[Breast cancer]] | ||
| + | *[[Cholangiocarcinoma]] | ||
| + | *[[Diffuse large B-cell lymphoma]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | **[[Esophageal adenocarcinoma]] | ||
| + | *[[Gallbladder cancer]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| − | *[[ | + | *[[Hepatocellular carcinoma]] |
| + | *[[Classical Hodgkin lymphoma]] | ||
| + | *[[Nasopharyngeal carcinoma]] | ||
| + | *[[Osteosarcoma]] | ||
| + | *[[Small cell lung cancer]] | ||
| + | *[[Soft tissue sarcoma]] | ||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Ovarian cancer - historical|Ovarian cancer]] | ||
| + | *[[Pancreatic cancer - historical|Pancreatic cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/druginfo/epirubicin.aspx Epirubicin (Ellence) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/epirubicin.aspx Epirubicin (Ellence) patient drug information (Chemocare)]</ref> |
*Brief patient counseling information can be found on [http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050778s015s017s018lbl.pdf#page=15 pages 15-16 of the Epirubicin (Ellence) package insert]<ref name="insert"></ref> | *Brief patient counseling information can be found on [http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050778s015s017s018lbl.pdf#page=15 pages 15-16 of the Epirubicin (Ellence) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/epirubicin-patient-drug-information Epirubicin (Ellence) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/epirubicin-patient-drug-information Epirubicin (Ellence) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/epirubicin-patient-drug-information Epirubicin (Ellence) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/epirubicin-patient-drug-information Epirubicin (Ellence) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 1999-09-15: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary [[breast cancer]]. ''(Based on FASG 05 & NCIC-CTG MA.5)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | ''The approval of this drug pre-dates the EMA.'' | ||
| + | *1982-06-28: EURD | ||
| + | ==Also known as== | ||
| + | *'''Generic name:''' 4-epi-doxorubicin, epidoxorubicin | ||
| + | *'''Brand names:''' Alrubicin, Anthracin, Binarin, Bioepicyna, Crisabon, E.P.R Elvetium, Ellence, Epidoxo, Epifil, Epilem, Epirubicine, Epizin, Epricin, Eracin, Famorubicin, Farmorubicin, Farmorubicina, Farmorubicine, Pharmorubicin, Riboepi, Rubifarm | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Intravenous medications]] |
| − | [[Category:Vesicant | + | [[Category:Vesicant]] |
| + | |||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
| − | [[Category:DNA synthesis inhibitors]] | + | [[Category:Human DNA synthesis inhibitors]] |
| − | [[Category: | + | |
| + | [[Category:Bladder cancer medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| + | [[Category:Cholangiocarcinoma medications]] | ||
| + | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| + | [[Category:Esophageal adenocarcinoma medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Gallbladder cancer medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
| − | [[Category: | + | [[Category:Hepatocellular carcinoma medications]] |
| + | [[Category:Classical Hodgkin lymphoma medications]] | ||
| + | [[Category:Nasopharyngeal carcinoma medications]] | ||
| + | [[Category:Osteosarcoma medications]] | ||
| + | [[Category:Small cell lung cancer medications]] | ||
| + | [[Category:Soft tissue sarcoma medications]] | ||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
| + | |||
| + | [[Category:Ovarian cancer medications (historic)]] | ||
| + | [[Category:Pancreatic cancer medications (historic)]] | ||
| + | |||
| + | [[Category:FDA approved in 1999]] | ||
| + | [[Category:EMA approved in 1982]] | ||
Revision as of 14:13, 29 December 2023
General information
Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. Inhibits DNA helicase activity, preventing enzymatic separation of double-stranded DNA.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bladder cancer
- Breast cancer
- Cholangiocarcinoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Osteosarcoma
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
Diseases for which it was used
Patient drug information
- Epirubicin (Ellence) patient drug information (Chemocare)[3]
- Brief patient counseling information can be found on pages 15-16 of the Epirubicin (Ellence) package insert[1]
- Epirubicin (Ellence) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1999-09-15: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. (Based on FASG 05 & NCIC-CTG MA.5)
History of changes in EMA indication
The approval of this drug pre-dates the EMA.
- 1982-06-28: EURD
Also known as
- Generic name: 4-epi-doxorubicin, epidoxorubicin
- Brand names: Alrubicin, Anthracin, Binarin, Bioepicyna, Crisabon, E.P.R Elvetium, Ellence, Epidoxo, Epifil, Epilem, Epirubicine, Epizin, Epricin, Eracin, Famorubicin, Farmorubicin, Farmorubicina, Farmorubicine, Pharmorubicin, Riboepi, Rubifarm
References
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Anthracyclines
- Topoisomerase II inhibitors
- Human DNA synthesis inhibitors
- Bladder cancer medications
- Breast cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Osteosarcoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Ovarian cancer medications (historic)
- Pancreatic cancer medications (historic)
- FDA approved in 1999
- EMA approved in 1982